Celularity Inc. (CELU)
- Previous Close
3.0700 - Open
3.0800 - Bid --
- Ask --
- Day's Range
2.8948 - 3.3600 - 52 Week Range
1.5900 - 8.9000 - Volume
48,969 - Avg. Volume
96,312 - Market Cap (intraday)
65.784M - Beta (5Y Monthly) 0.30
- PE Ratio (TTM)
-- - EPS (TTM)
-10.3000 - Earnings Date May 20, 2024 - May 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
www.celularity.comRecent News: CELU
Performance Overview: CELU
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CELU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CELU
Valuation Measures
Market Cap
65.78M
Enterprise Value
126.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.61
Price/Book (mrq)
2.17
Enterprise Value/Revenue
8.56
Enterprise Value/EBITDA
-0.75
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.48%
Return on Equity (ttm)
-186.55%
Revenue (ttm)
14.79M
Net Income Avi to Common (ttm)
-181.41M
Diluted EPS (ttm)
-10.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
273k
Total Debt/Equity (mrq)
201.93%
Levered Free Cash Flow (ttm)
-15.24M